Founder and Executive Chairman Mr. Bill Mobbs has released a parcel of his 42% of ITL (4.6m shares) to a Specialist Small Cap Fund Manager and to fellow ITL non-executive Director Mr. Mark Peatey. Mr. Mobbs retains 36% of ITL.
Essentials for Blood Management and Clinical Procedures
ITL BioMedical enables best clinical outcomes through innovative tools for blood management and clinical procedures. As a global provider of blood management and clinical procedure tools with a significant portfolio of intellectual property, we consistently look to the future and leverage input from healthcare markets worldwide to advance our products. Our world-class manufacturing facility and R&D lab develops and rigorously tests our advancements ensuring our innovations are designed with the utmost quality for introduction on a global basis.
ITL BioMedical enables best clinical outcomes through innovative tools for blood management and clinical procedures. As a global provider of blood management and clinical procedure tools with a significant portfolio of intellectual property, we consistently look to the future and leverage input from healthcare markets worldwide to advance our products. Our world-class manufacturing facility and R&D lab develops and rigorously tests our advancements ensuring our innovations are designed with the utmost quality for introduction on a global basis.
Read More
